BioWorld

Aug. 30, 2010

Genentech Caught off Guard, FDA Issues Refuse-to-File for T-DM1

The FDA sent a refuse-to-file letter to Genentech Inc., a member of the Roche Group, rejecting the company's application for accelerated approval of trastuzumab-DM1 (T-DM1) and catching investors and the company off guard. (BioWorld Today) Read More

Otonomy Lures New Investors with $38.5M Series B Financing

Senate to Hold Hearing on Funding for Stem Cells

FDA Oversteps its Bounds for Jazz Fibromyalgia Drug

Genzyme's ERT Rationing to End Soon; Sanofi Still Biting?

Corrections & Clarifications

Clinic Roundup

Stock Movers

Financings Roundup

Other News To Note

U.S. Patent Disclosures

Bench Press

Today's news in brief

BioWorld

BioWorld briefs for July 31, 2026.

AIDS 2026: New targets for metabolic dysfunction despite ART

BioWorld

Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...

Jingxin discloses new muscarinic and sigma receptor agonists

BioWorld Science

Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...

Silhouette illustration of DNA gene editing

Death in Chinese gene-editing trial exposes ethical fault lines

BioWorld

The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...

Fauci’s silence may put him in contempt of Congress

BioWorld

After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...